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Abstract: Skin cancer, which includes melanoma and squamous cell carcinoma, represents the most
common type of cutaneous malignancy worldwide, and its incidence is expected to rise in the near
future. This condition derives from acquired genetic dysregulation of signaling pathways involved
in the proliferation and apoptosis of skin cells. The development of animal models has allowed a
better understanding of these pathomechanisms, with the possibility of carrying out toxicological
screening and drug development. In particular, the zebrafish (Danio rerio) has been established as one
of the most important model organisms for cancer research. This model is particularly suitable for
live cell imaging and high-throughput drug screening in a large-scale fashion. Thanks to the recent
advances in genome editing, such as the clustered regularly-interspaced short palindromic repeats
(CRISPR)/CRISPR-associated protein 9 (Cas9) methodologies, the mechanisms associated with cancer
development and progression, as well as drug resistance can be investigated and comprehended.
With these unique tools, the zebrafish represents a powerful platform for skin cancer research in
the development of target therapies. Here, we will review the advantages of using the zebrafish
model for drug discovery and toxicological and phenotypical screening. We will focus in detail on
the most recent progress in the field of zebrafish model generation for the study of melanoma and
squamous cell carcinoma (SCC), including cancer cell injection and transgenic animal development.
Moreover, we will report the latest compounds and small molecules under investigation in melanoma
zebrafish models.
Keywords: melanoma; squamous cell carcinoma; inhibitor screening; transgenic zebrafish;
skin cancer; drug development
1. Introduction
Zebrafish is a small vertebrate tropical fish that has recently emerged as one of the most useful
models for studying human diseases, including cancers. In fact, zebrafish displays high fecundity
and is suitable for genetic manipulation and both reverse and forward genetic studies. Thanks to
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its relatively low cost of use, the zebrafish is ideal for large-scale screening approaches and allows
both chemical and genetic screening to identify genes and pathways underlying diseases, as well as
phenotypic screening for the discovery of new drugs [1,2]. The compounds, drugs or small molecules,
can be added directly to the water environment of the zebrafish [3]. Moreover, given the high genetic
and physiological similarities with humans, zebrafish can be used as a useful and cost-effective vehicle
for high-throughput screening (HTS) [2,4–6].
The growing interest in this model is derived from the optical transparency of zebrafish
embryos and larvae, as well as their fast development ex utero. In fact, zebrafish are capable of
fertilizing 200–300 eggs every 5–7 days and have an equivalent longevity and generation time to mice
(3–5 months). Zebrafish embryos rapidly develop ex utero, and less than one week is required for the
development of the digestive, nervous and cardiovascular organ systems [7–12]. This property allows
for faster study of the physiological and pathological mechanisms by a direct live-cell imaging in vivo.
For these reasons, zebrafish has become an important model for human diseases. Moreover, the high
level of similarity between human and zebrafish larvae in terms of the genetics and physiology of the
innate immune system promotes special investigation on cancer research [1]. Zebrafish is a suitable
model for tumor induction by the use of several methods, such chemical treatments [13], genetic
knockout [14], gene overexpression [15] and xenotransplantation [16]. Zebrafish has been used for the
study of different type of cancers, such as skin cancer [14,15] pancreatic cancer [16], breast cancer [17],
leukemia [18], glioma [19] and lung cancer [20].
Skin cancer, which includes melanoma and squamous cell carcinoma (SCC), represents the most
common type of cutaneous malignancy worldwide, and its incidence is expected to rise in the near
future [21]. Melanoma is the deadliest form of skin cancer, with respect to all skin cancer-related
deaths, and has a mortality rate of 80% [22,23]. Melanoma arises from melanocytes, the pigmented
epidermal cells responsible for the production of melanin. In the early stages, melanoma is confined to
the epidermis (radial growth phase (RGP) melanoma) and can be removed by surgical excision [24].
These types of melanomas are usually associated with a good prognosis. On the contrary, in the next
stages of tumor progression, melanoma cells invade the subcutaneous tissues (vertical growth phase
(VGP) melanoma) and eventually progress toward the metastatic phase. At this stage, few therapeutic
options are available, and melanoma frequently relapses and becomes incurable [6,24].
Cutaneous SCC (cSCC) mostly derives from alterations within the epidermal homeostasis caused
by ultraviolet exposure and relies on uncontrolled proliferation of the epidermal cells, namely
keratinocytes [25]. cSCC is the second most frequent type of non-melanoma skin cancer and represents
20% of all skin malignancies [25,26]. Although in situ SCCs are curable by surgical excision, metastatic
SCCs are responsible for the majority of deaths due to non-melanoma skin cancers [21]. As a
keratinocyte-derived epithelial tumor, head and neck squamous cell carcinoma (HNSCC) arises
in several places in the head and neck region, such as oropharynx and laryngopharynx, and is
very common worldwide, representing 4% of all cancers in the United States [23]. In particular,
oral squamous cell carcinoma (OSCC) accounts for 24% of HNSCC with a mortality rate of 200,000
cases each year [26,27]. Despite different therapeutic options, such as radio or chemotherapy or surgery,
the five-year survival rate is approximately 50% [26,28,29].
Given the significant impact of melanoma and SCC, on a world-wide scale, the development of
new tools to study these pathologies and their treatment represents an important task. In the present
review, we describe the zebrafish as a powerful in vivo model for skin cancer (melanoma and SCC)
and summarize the advantages of drug screening in skin cancer research. We report in detail on the
use of transgenic zebrafish to study melanoma development, progression and treatment [30,31] and
the use of zebrafish embryos to evaluate potential targets and compounds for SCC [22,25].
1.1. Zebrafish as a Model Organism for Pharmacological and Toxicological Screening
In recent years, research has begun to develop an understanding of how zebrafish can be used
as an in vivo model for human diseases, in terms of targets for therapy, physiological similarity,
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drug metabolism, drug safety and toxicity and pharmacology [2] (Figure 1). The zebrafish genome
shares over 70% similarity with the human genome, and over 80% of known human disease genes,
including oncogenes and tumor suppressor genes, have orthologues in zebrafish [32]. Several pathways
are also well conserved between human and zebrafish allowing targeting of a specific biological
process [32]. Therefore, the results obtained by using zebrafish models for drug screening can be
particularly relevant for human disease and cancer therapy.
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screened in zebrafish with effects similar to humans.  
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screening in zebrafish overcomes this problem; moreover, there are physiological similarities in the 
blood brain barrier [10], endothelial cells [33], endothelial cells and immunological responses [34], 
giving fast data related to the pharmacological characteristics [35–37]. When injected with a 
compound, either a drug or small molecule, zebrafish and mammals present overlapping physiologic 
responses, such as the induction of metabolites, enzyme activity against different antigens and upon 
oxidative stress conditions [4,9]. 
A number of the biological properties of zebrafish provides advantages for drug screening. 
Early-stage zebrafish embryos have a transparent body, making it relatively easy to collect numerous 
data using a high-quality imaging after treatment. Moreover, given that a single female can lay  
10,000 eggs per annum [38], it is possible to reach high throughput (1000–10,000) or more assays per 
day, as only space becomes a limiting factor [39] (Figure 2). For this reason, zebrafish embryos have 
been proposed as the in vivo animal model that could bridge the gap between cell-based assays and 
biological validation of a compound. Moreover, the presence of the chorion, an acellular envelope 
made of three intercrossing layers that surround the embryo during development, allows some 
materials to easily pass through to the embryo via passive diffusion [40]. This aspect is relevant in 
terms of physical-chemical properties of the compounds that could be tested by zebrafish models, by 
affecting the efficacy of the treatments or the level of dose-specific toxicity.  
Because of the transparency of zebrafish embryos and larvae and the possibility to conduct 
morphological observation of various organs and anatomic structures during development [8,10–
12,41], zebrafish has assumed an important role in toxicology research, including ecotoxicology and 
developmental studies. The greatest advantage of zebrafish in toxicology studies is the low cost with 
respect to rodents and the possibility to perform analysis with a larger number of compounds at the 
same time. In this respect, zebrafish can be utilized for large-scale screening of compounds/libraries 
and drugs, as it may give faster results. In fact, hundreds of different hits from a primary HTS can be 
Figure 1. Zebrafish as a relevant model for human disease and cancer therapy. The zebrafish genome
shows up to 80% similarity with human disease-associated genes. Moreover, thanks to a well-conserved
physiology, the pharmacological behavior and metabolism of several drugs have been screened in
zebrafish with effects similar to humans.
Cell-based assays mostly provide limited results and information about the absorption,
distribution, metabolism and toxicity of the screened molecules, compounds and drugs. By contrast,
screening in zebrafish overcomes this problem; moreover, there are physiological similarities in the
blood brain barrier [10], endothelial cells [33], endothelial cells and immunological responses [34],
giving fast data related to the pharmacological characteristics [35–37]. When injected with a compound,
either a drug or small molecule, zebrafish and mammals present overlapping physiologic responses,
such as the induction of metabolites, enzyme activity against ifferent antigens and upon oxidative
stress conditions [4,9].
A number of the biological properties of zebrafish provides advantages for drug screening.
Early-stage zebrafish embryos have a transparent body, making it relatively easy to collect numerous
data using a high-quality imaging after treatment. Moreover, given that a single female can lay
10,000 eggs per annum [38], it is possible to reach high throughput (1000–10,000) or more assays per
day, as only space becomes a limiting factor [39] (Figure 2). For this reason, zebrafish embryos have
been proposed as the in vivo animal model that could bridge the gap between cell-based assays and
biological validation of a compound. Moreover, the presence of the chorion, an acellular envelope made
of three intercrossing layers that surround the embry during development, allows some materials
to easily pass thr ugh to the embry via passive diffusion [40]. This aspect i relevant i terms of
physical-c emical properties of the c mp unds that could be tested by zebrafish m dels, by affecting
the efficacy of the treatments or the level of dose-specific toxicity.
Because of the transparency of zebrafish embryos and larvae and the possibility
to conduct morphological observation of various organs and anatomic structures during
development [8,10–12,41], zebrafish has assumed an important role in toxicology research, including
ecotoxicology and developmental studies. The greatest advantage of zebrafish in toxicology studies
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is the low cost with respect to rodents and the possibility to perform analysis with a larger number
of compounds at the same time. In this respect, zebrafish can be utilized for large-scale screening of
compounds/libraries and drugs, as it may give faster results. In fact, hundreds of different hits from a
primary HTS can be tested to eliminate the toxic compounds and then prioritizing those that will be
utilized in further assays and drug development. This implicit counter-screen for toxicity is an integral
part of disease suppressor screens in the organism [2].
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Figure 2. Zebrafish model for high-throughput drug screening. Zebrafish is a valuable tool for
high-throughput screening assays. In terms of toxicity, zebrafish have been used to evaluate a specific
organ or behavior with respect to toxicity. In drug screening, zebrafish is also established as precious
platform to multipl systemic phenotype studies simultaneously with metabolic profiles and toxicity
reporter lines.
In addition, th transplantation of human cancer cells into zebrafish to generate xenograft models
represents a powerful tool to monitor cancer proliferation, tumor angiogenesis, metastasis and drug
response in real time.
The use of fluorescent probes or reporter genes during toxicological or cancer-related studies
gives the opportuni y o perf rm live-imaging for both transgenic and xenotransplantation
models. For example, melanoma cells can be stained with Vybrant Cell-Labeling Solution or
(5(6)-Carboxyfluorescein N-hydroxysuccinimidyl ester (CFSE) dye before being microinjected in
the yolk [42]. To identify the role of Raf and phosphoinositide 3-kinase (P13K) signaling pathways
in melanoma cells, a Green Fluorescent protein (GFP) reporter g ne was used und r the control
of the promoter of the melanoma cell specific gene, microphthalmia-associated transcription factor
(mitf ) [24]. Similarly, in order to investigate the implication of Extracellular signal-Regulated kinases
(ERK1/2)-Mitogen-Activated Protein kinases (MAPK) signaling pathways in the development of uveal
melanoma, transg nic embryos were labeled with GFP nd coupled to the GNAQQ209P vector in
order to express this oncogene in melanocytes [30]. Moreover, inter-segmental blood vessel cells were
labeled with GFP in transgenic embryos for the study of melanoma cell adhesion [15].
Nevertheless, as a consequence of the complexity and inherent differences of mammals, it is
important to highlight that zebrafish can never replace rodents in the later phases of drug discovery, but
may be complementary to rodent or cell-based assays at earlier stages [43]. Indeed, clinical trials using
several murine models for huma inflamm tory pathologies fail to show a significa t success rate in
humans [44]. Hence, understanding the advantages, disadvantages and limitations of mammalian
models helps to choose the best model for pharmacological studies according to the specific target.
1.2. Phenotype-Guided Drug Discovery
Despite the achievement of significant progress in drug discovery, the identification of new
therapeutic targets for the treatment of human diseases remains a big challenge in science [45].
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While previous studies were restricted to invertebrate model organisms, such as Caenorhabditis
elegans, or to in vitro cell-based assays, because of extensive labor and cost requirements, the use of
zebrafish has opened a new avenue [45]. Thanks to the random mutagenesis strategy, a greater range
of phenotypes resembling human diseases can be investigated in comparison to other vertebrates
such as mice and rats. In contrast to target-based approaches, phenotype-guided drug discovery
aims to carry out a large chemical screening by combining HTS with animal models for a human
disease. Hence, using the phenotype-guided drug discovery, it is possible to identify an effective
compound by looking at phenotype alteration in the whole organism, independently of the specific
target. Therefore, this approach improves the development of new drugs and, at the same time, allows
the identification of the pathways that are implicated in the development or progression of the specific
disease [6]. Two examples of the use of zebrafish for phenotype-based drug discovery are given by
the screening of chemical molecules as suppressors of two specific genetic mutations: (1) gridlock
and (2) Crumbs homolog (crb) mutations [45]. Gridlock mutants, which present a vascular defect
due to a mutation in the hey2 gene, have been treated with a library of 5000 small molecules to revert
the disease phenotype. From the screening, two compounds, named GS4012 and GS3999, have been
identified. These molecules activate the vascular endothelial growth factor (VEGF) pathway to rescue
the pathological phenotype. The second mutant harbors a mutation in the Myb proto-oncogene protein
also known as transcriptional activator Myb (myb) gene, which leads to genome instability and defects
in the cell-cycle. A library of 16,320 compounds was screened in crb embryos, allowing the discovery
of three different classes of suppressors of the crb mutant phenotype. The possibility to report human
disease alleles in zebrafish further supports the high impact of this method in drug discovery [46–49].
2. Zebrafish as a Model Organism to Study SCC
The zebrafish model has been recently used to identify key molecules in cSCC and HNSCC [23],
as well as compounds for SCC target therapy [50].
Cichon and co-workers found that the tyrosine kinase receptor Axl, which is highly expressed in
SCC where it promotes cell survival, is implicated in tumor formation in the cSCC xenograft model
in zebrafish [51]. Indeed, Axl deletion in cSCC cells reduced tumor mass, after cell injection in the
yolk sac of one-day-old embryos, thus indicating that Axl is a potential therapeutic target for SCC.
Using a similar approach, the role of type VII collagen (Col7) in cSCC tumor growth and angiogenesis
was also evaluated. Mutation in the COL7A1 gene is responsible for dystrophic epidermolysis bullosa
(RDEB), an inherited blistering disorder that predisposes to the development of an unexplained
aggressive SCC [25]. Recombinant type VII collagen (hrCol7) was able to reverse SCC angiogenesis in
the xenograft model [25].
The tyrosine kinase discoidin domain receptor 2 (DDR2), which has a role in cell proliferation,
adhesion, differentiation and invasion, is implicated in HNSCC [21]. DDR2 has been reported to be
inhibited by dasatinib, a Food and Drug Administration (FDA)-approved inhibitor of Abelson murine
leukemia viral oncogene homolog, Proto-oncogene tyrosine-protein kinase (ABL, SRC) and c-Kit [21].
Von Massenhausen and collaborators analyzed the functional role of DDR2 in an in vivo xenograft
model with or without dasatinib treatment and demonstrated that DDR2 inhibition blocked HNSCC
cell migration and invasion [21]. Their research indicates that dasatinib can be potentially used as a
tyrosine kinase inhibitor in DDR2-positive HNSCC patients.
Zebrafish embryos have also been used to evaluate the effect of Flotillin-1 overexpression in
KB cells (a subline of the KERATIN-forming tumor cell line HeLa), which are an OSCC cell line [26].
Flotillin-1 is a component of the lipid rafts and plays an essential role in cell adhesion, cell morphology
and protein secretion [26]. Zebrafish embryos were injected with fluorescent-labeled tumor cells
overexpressing Flotillin-1 to analyze tumor metastasis. The results demonstrated that the expression
of Flotillin-1 increases the cell growth and motility of KB cells [26].
The motility of OSCC was also targeted by the use of the neutralizing monoclonal antibody NZ-1
and lectin (MASL) against podoplanin (PDPN)-expressing OSCC cells in zebrafish. This molecule
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is a transmembrane receptor that promotes tumor cell motility in OSCC, and it might be used as a
chemotherapeutic target for primary and metastatic cancers [6].
Among the compounds being evaluated in zebrafish for SCC, triazine compound S06 reduces
OSCC invasion. Its mechanism of action is targeting of the chaperon heat-shock protein 90 (Hsp90);
thus, inhibiting carcinoma-associated fibroblast (CAF)-derived proinvasive chemokinases by S06 is
capable of inhibiting tumor cell migration in a zebrafish xenograft model at 48 h post-fertilization [50].
The marine microbial extract luminacin was evaluated in zebrafish embryos in terms of anti-tumor
activity in HNSCC [23]. Luminacin treatment of cancer cells was able to inhibit growth and cancer
progression by promoting autophagy of HNSCC cell lines.
Taken together, these works well support the use of zebrafish as a model organism for the
analysis of the key players in SCC development and progression, as well as for drug screening and
toxicity assays.
3. Zebrafish as Model Organism for Melanoma Research
While the importance of the activation of oncogenes and inactivation of tumor suppressor genes in
tumor formation is well appreciated, our understanding of the early events of cancer initiation remains
limited. The mechanisms that enable a subpopulation of tumor cells to complete the conversion to
a malignant state among a larger group of cancer-prone cells (described as a “cancerized field”) is
still unclear [52]. To better understand the mechanisms underlying tumor initiation, in melanoma
research, zebrafish can be used as an excellent tool, through the use of xenograft [42,53] and transgenic
models [30,54].
The main advantages of xenotransplantation are live cell imaging and the lack of the adult
immune system, which is completely functional only at 28 days of development. The injection of
fluorescent-labelled melanoma cells into zebrafish larvae enables the study of cancer angiogenesis and
tumor cell spread. The early phases of melanoma progression and the phenotype switching toward
metastatic behavior have been recently investigated in zebrafish through the study of the neurotrophin
receptor CD271 (p75NTR) [42]. CD271 is variably expressed in melanoma cells, showing higher levels
in primary tumors compared to the metastatic tumors derived from the same patient. The injection of
melanoma cells after CD271 silencing or overexpression in transparent larvae revealed that CD271
absence is associated with a higher number of metastases in zebrafish [42].
Since adult zebrafish are no longer transparent, in order to visualize melanoma cells by fluorescent
gene expression, a transparent adult fish, named casper, has been created by White et al. [55].
Alternatively, the study of melanoma development can be performed in transgenic zebrafish
derived from the expression of oncogenes or from mutations in tumor suppressor genes induced with
N-ethyl-N-nitrosourea (ENU). ENU is a powerful mutagen with alkylating activity used as a highly
efficient strategy to induce random mutations in the genome of zebrafish. This approach consists of
exposing zebrafish to repeated treatments with ENU to generate point mutations in pre-meiotic germ
cells [53]. This treatment causes all possible base pair changes, such as nonsense, splicing and missense
mutations. ENU has been successfully used to create a series of knockout zebrafish [56]. Given
that the phenotype associated with alterations in the zebrafish development was easily noticeable,
ENU was used to investigate the role of mutations in embryonic patterning and development. However,
some disadvantages limited the use of this random mutagenesis approach, such as the generation of
heterozygous mutants that hamper the identification of recessive inherited phenotypes. By using this
approach, three mutants named “young” (Yng), “perplexed” (plx) and “confused” (cfs) affected by defects
in retinal lamination have been identified [57]. More recently, the clustered regularly-interspaced
short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has emerged as a new
genome editing tool to induce mutations in specific genes within organisms [58]. CRISPR comprises
segments of DNA containing short, repetitive base sequences. These sequences play a role in a bacterial
immune system. The CRISPR/Cas9 strategy is based on delivering the Cas9 DNA nuclease with a
guide RNA (gRNA) into a cell to cut the genome at a specific location. A series of successful studies
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used this technology to evaluate the role of specific genetic perturbations on the phenotype of zebrafish.
For example, it has been used to study the effect of MMP21 knock-out, revealing a role in cardiac
defects and alteration of Notch signaling [59]. Moreover, this genome editing system has a great impact
in cancer research, as it permits tissue-specific modelling of human cancer, such as melanoma [60–62].
Melanoma frequently originates due to mutation in the BRAF and NRAS genes (43% and 30% of
cases, respectively) [63]. Because BRAF acts as a serine/threonine kinase and becomes activated by
a somatic point mutation, it plays an important role as a target for drug development in malignant
melanoma [64]. The first melanoma zebrafish model carrying the V600E mutation was obtained
by placing the human BRAFV600E gene under the control of the mitf (microphthalmia-associated
transcription factor) promoter, a transcription factor involved in the lineage-specific pathway of
melanocytes [65]. The BRAFV600E mutation is associated with melanoma development; however,
the concomitant loss of function of the p53 gene is needed to make melanocytic naevi progress to
cancer [64]. Even after the generation of an extensive “cancerized field”, with all melanocytes harboring
both BRAFV600E and p53-/- mutations in zebrafish, only one to three melanomas will develop and only
after several months [65]. This lesser number and time frame indicate that other molecular alterations
and pathways play an important role in tumor formation. By screening the genes implicated in
the rapid onset of melanoma, Zon and colleagues found that the overexpression of histone-lysine
N-methyltransferase (SETDB1) can accelerate the onset and invasion of melanoma [4]. High levels
of SETDB1 are common in human melanoma, indicating that chromatin remodeling may be critical
in melanoma progression due to changes in gene regulation, such as subset of homeotic genes (hox)
genes [66].
Transgenic zebrafish carrying RAS mutations for the study of melanoma have also been
created [24]. Expression of the HRASG12V protein, under the mitfa promoter, in melanocyte progenitors
induces a hyper-pigmented phenotype and an abnormal growth of melanocytes in the larvae;
ultimately driving melanoma formation in the adult fish [67]. Moreover, elevated activity of RAC,
a subfamily of Rho GTPases, often associated with melanoma in humans, can accelerate the progression
of HRASV12-driven malignant melanoma [68]. Zebrafish BRAFV600E models have some limitations,
such as the time needed for spontaneous tumor formation and the different number of mutations as
compared to human melanomas [69]. On the other hand, HRASV12 mutations accelerate melanoma
formation and enable melanoma to be visualized at the earliest stages in zebrafish [7,24,70].
Finally, the zebrafish model allows the study of genes involved in the lineage-specific pathway
for melanocyte development and how their misregulation is responsible for melanoma initiation [71].
For this purpose, a temperature-sensitive zebrafish model harboring a mutation in the mitf gene
(mitfavc7) has recently been created [71–73].
4. Compounds and Inhibitors for Melanoma Treatment
Previous studies have shown that mitf is a potential therapeutic target for melanoma
treatment [67,74,75]. MITF plays a critical role in the development of the melanocytic lineage [76,77] and
regulates genes associated with melanogenesis, cell differentiation, proliferation and survival [78–80] by
targeting BCL-2 (B-cell leukemia/lymphoma 2) [81], ML-IAP (melanoma inhibitor of apoptosis) [82,83],
HIF1a (hypoxia-inducible factor 1a) [84] and MET [85]. Moreover, MITF can regulate the expression
of CDKN1A [86,87], which encodes for p21, an inhibitor of the cell-cycle. Through screening of
a small molecule library containing 2000 compounds, SKLB226 has been identified as a specific
suppressor of mitf expression, subsequently able to inhibit the viability and migration of melanoma
cells [88]. In addition, the evaluation of SKLB226 action in zebrafish showed its ability to block
pigmentation and cell migration in vivo [89]. Levi et al. used zebrafish embryos to test a library of
6000 compounds identifying two molecules (12G9 and 36E9) able to inhibit melanocyte development
by targeting mitf [90]. 12G9 and 36E9 inhibited pigmentation of both skin and retinal pigment
epithelium [91] and induced apoptosis of melanocytes [76]. In particular, the compounds impaired
the proliferation and differentiation of melanoblasts and induced a reduced number of mitfa and
Int. J. Mol. Sci. 2017, 18, 1550 8 of 15
dct (dopachrome tautomerase, a protein required for the synthesis of eumelanin) positive cells [91].
In addition, among the sulfur-containing molecules, 4 (phenylsulfanyl) butan-2 reduces the expression
of melanin synthesis-related proteins and exhibits a good safety profile. This compound induces a
remarkable suppression of melanogenesis in zebrafish after 48 h. In addition, its ability to repress
in vivo pigmentation could have significant applications in the cosmetic field [91]. Furthermore,
this whitening substance is safe and effective, and it could be used to prevent hyper-pigmentation [91].
Zebrafish embryos carrying BRAFV600E expression have been used for the study of the neural
crest-derived cell lineage [92]. In particular, transgenic mitf-BRAFV600E; p53/zebrafish embryos have
been created for the evaluation of early transcriptional activity within melanoma pathogenesis and to
provide a model for chemical genetic screening in the context of melanoma therapy.
Inhibitors of dihydroorotate dehydrogenase (DHODH), such as leflunomide (lef), are able to
reduce the ability of self-renewal of neural crest cells and target the activity of those genes required
for neural crest development and melanoma tumor growth [93], including mitf and myc targets [92].
Research data suggest that lef would be more effective in combination with a BRAFV600E inhibitor
and may help to overcome resistance to BRAFV600E inhibitors. Current goals involve the identification
of more lineage-specific suppressors in zebrafish embryos that can be generalized to other cell types,
with less side effects and toxicity and direct relevance to human cancer.
The inhibition of DHODH by lef ablates zebrafish neural crest development and suppresses
melanoma growth by blocking the transcriptional elongation of key genes, such as crestin and
mitfa [92]. HEXIM1 (hexamethylene bisacetamide inducible 1) works as a general RNA polymerase II
transcription inhibitor, and its expression regulates gene expression during differentiation. HEXIM1
suppresses melanoma tumors in response to nucleotide stress, and its overexpression in a zebrafish
model suppresses melanoma formation [94]. HEXIM1 knockdown by morpholinos partially rescued
crestin and mitfa expression in lef treated zebrafish embryos [94]. This mechanism involves control of
the elongation phase of RNA transcription and regulates gene expression during differentiation [93].
The function of HEXIM1 in melanoma was investigated after its overexpression and deletion in a
zebrafish model, revealing its role as a tumor suppressor gene. Other cell types may be susceptible to
different cellular stresses and respond in a similar manner by activating HEXIM1 to help the cell repair
or induce cell death. Finding such dependencies in other cancers could lead to the development of
new cancer therapies using the zebrafish model (Figure 3) [62,95].
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Figure 3. The tumor suppressor hexamethylene bisacetamide inducible 1 (HEXIM1) gene inhibits
melanoma in the zebrafish model. HEXIM1 plays an important role as a melanoma tumor suppressor
in response to nucleotide stress. HEXIM1 forms a complex with positive transcription elongation
factor (P-TEFb) in order to inhibit the kinase to initiate transcription elongation at tumorigenic genes.
Alteration of gene expr ssion, i parallel with anti-tumorigeni RNAs binding to HEXIM , favors
the “anti-ca cer” gene expression. Pol II: DNA polymerase II; CDK9: cyclin-dependent kinase;
CCNT1: Cyclin-T.
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A transgenic zebrafish melanoma model was developed by coupling the zebrafish mitfa
promoter with the human oncogenic HRASG12V [96]. These transgenic embryos developed
melanocyte hyperplasia with the induction of RAS-RAF-MEK-ERK and RAS-PI3K-AKT-mTOR
signaling pathways. In this context, the zebrafish model was useful for the screening of compounds
directed against mitogen-activated protein kinases, extracellular signal-regulated kinases (MEK/ERK)
and PI3K/mTORi pathways, alone or in combination. Rapamycin, a well-known mTOR inhibitor,
is considered as one of the strongest drugs in the field [97]. It was suggested that rapamycin analogs
might also improve access to the kinase active site of ATP competitive inhibitors. The ability of
rapamycin analogs to co-operate with MEKi to suppress melanoma cell growth was previously
observed. Because of the efficacy of cocktails of inhibitors observed with HTS assays in vitro, clinical
trials using rapamycin analogs combined with MEKi or PIK3K/mTORi are currently underway [98]
(Figure 4).
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inhibitors. Zebrafish plays an important role for the screening of compounds targeting MEK/ERK and
PI3K/mTOR pathways, both alone and in combination. (A) Example of screening of the FDA library
molecules using zebrafish embryos; (B) steps showing hit selection after the screening procedure with
different drugs and drug dose response using the melanin assay. At the end of this process, 11 hits
were detected to be further evaluated in cell culture. MEKi: mitogen-activated protein kinases inhibitor;
PI3K: phosphoinositide 3-kinase; mTOR: mechanistic target of rapamycin.
5. Conclusions and Future Directions
As zebrafish research develops further, new knowledge and tools are becoming available that will
significantly impact the range and quality of in vivo chemical screening. Recent and future advances
in zebrafish research will certainly have an impact that will include improvements in data acquisition
(particularly imaging), increased automation capability, advances in genetic manipulation and the
development of new phenotypic endpoints. A new era of combined therapy for metastatic melanoma
is now on the way. To further address the development of resistance, clinical trials involving triple
combination therapies are ongoing. In this respect, the combination of BRAF and MEK inhibitors with
anti-ErbB3 antibodies, at least based on preclinical data, predicts a future clinical use.
Replacing the target-based drug discovery with the newly-introduced phenotype-guided
discovery has opened an important gate for chemical and genetics screening. HTS in combination
with zebrafish as an in vivo disease model represents a valuable tool for toxicity studies and small
molecules screening. At the same time, a large number of molecules and compounds can be screened
with the use of zebrafish in order to identify effective drugs and observe disease phenotypes.
The incidence of skin cancer is showing a rapid increase worldwide for several reasons,
from unprotected exposure to the Sun to the aging of the population [68]. SCC and melanoma
are malignant conditions of the skin for which the need for drug development is crucial, because of
the number of patients with metastases and the poor outcome for advanced stages. In this context,
zebrafish models give the opportunity to both explore new pathways and test new compounds or small
Int. J. Mol. Sci. 2017, 18, 1550 10 of 15
molecules that could be used in clinical trials. Simultaneously, the effect on embryonic development
and toxicity is rapidly available and allows optimized targets and doses. Therefore, the development
of zebrafish models will help to bridge the gap between in vitro cell culture and in vivo mammalian
models for a rapid pre-clinical drug development.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Zhao, S.; Huang, J.; Ye, J. A fresh look at zebrafish from the perspective of cancer research. J. Exp. Clin.
Cancer Res. 2015, 34, 80. [CrossRef] [PubMed]
2. MacRae, C.A.; Peterson, R.T. Zebrafish as tools for drug discovery. Nat. Rev. Drug. Discov. 2015, 14, 721–731.
[CrossRef] [PubMed]
3. Rennekamp, A.J.; Peterson, R.T. 15 years of zebrafish chemical screening. Curr. Opin. Chem. Biol. 2015, 24,
58–70. [CrossRef] [PubMed]
4. Zon, J.; Miziak, P.; Amrhein, N.; Gancarz, R. Inhibitors of phenylalanine ammonia-lyase (PAL): Synthesis
and biological evaluation of 5-substituted 2-aminoindane-2-phosphonic acids. Chem. Biodivers. 2005, 2,
1187–1194. [CrossRef] [PubMed]
5. Peterson, R.T.; MacRae, C.A. Systematic Approaches to Toxicology in the Zebrafish. Annu. Rev. Pharmacol.
Toxicol. 2012, 52, 433–453. [CrossRef] [PubMed]
6. Fernandez Del Ama, L.; Jones, M.; Walker, P.; Chapman, A.; Braun, J.A.; Mohr, J.; Hurlstone, A.F. Reprofiling
using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics. Oncotarget 2016, 7,
40348–40361. [CrossRef] [PubMed]
7. Zonfrillo, M.R.; Penn, J.V.; Leonard, H.L. Pediatric psychotropic polypharmacy. Psychiatry 2005, 2, 14–19.
[PubMed]
8. Parng, C. In vivo zebrafish assays for toxicity testing. Curr. Opin. Drug Discov. Dev. 2005, 8, 100–106.
9. Rubinstein, A. Zebrafish: From disease modeling to drug discovery. Curr. Opin. Drug. Discov. Dev. 2003, 4,
218–223.
10. Schröder, U.; Sabel, B. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central
analgesic effects of i.v. dalargin injections. Brain Res. 1996, 710, 121–124. [CrossRef]
11. Teraoka, H.; Dong, W.; Hiraga, T. Zebrafish as a novel experimental model for developmental toxicology.
Congenit. Anom. 2003, 43, 123–132. [CrossRef]
12. Zon, L.I.; Peterson, R.T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 2005, 4, 35–44.
[CrossRef] [PubMed]
13. Mirbahai, L.; Williams, T.D.; Zhan, H.; Gong, Z.; Chipman, J.K. Comprehensive profiling of zebrafish
hepatic proximal promoter CpG island methylation and its modification during chemical carcinogenesis.
BMC Genom. 2011, 12, 3. [CrossRef] [PubMed]
14. Kaufman, C.K.; Mosimann, C.; Fan, Z.P.; Yang, S.; Thomas, A.J.; Ablain, J.; Tan, J.L.; Fogley, R.D.;
van Rooijen, E.; Hagedorn, E.J.; et al. A zebrafish melanoma model reveals emergence of neural crest
identity during melanoma initiation. Science 2016, 351, aad2197. [CrossRef] [PubMed]
15. Liu, C.J.; Xie, L.; Cui, C.; Chu, M.; Zhao, H.D.; Yao, L.; Li, Y.H.; Schachner, M.; Shen, Y.Q. Beneficial roles of
melanoma cell adhesion molecule in spinal cord transection recovery in adult zebrafish. J. Neurochem. 2016,
139, 187–196. [CrossRef] [PubMed]
16. Weiss, F.U.; Marques, I.J.; Woltering, J.M.; Vlecken, D.H.; Aghdassi, A.; Partecke, L.I.; Heidecke, C.D.;
Lerch, M.M.; Bagowski, C.P. Retinoic acid receptor antagonists inhibit miR-10a expression and block
metastatic behavior of pancreatic cancer. Gastroenterology 2009, 137, 2136–2145. [CrossRef] [PubMed]
17. Drabsch, Y.; He, S.; Zhang, L.; Snaar-Jagalska, B.E.; ten Dijke, P. Transforming growth factor-beta signalling
controls human breast cancer metastasis in a zebrafish xenograft model. Breast Cancer Res. 2013, 15, R106.
[CrossRef] [PubMed]
18. Zhang, B.; Shimada, Y.; Kuroyanagi, J.; Umemoto, N.; Nishimura, Y.; Tanaka, T. Quantitative phenotyping-
based in vivo chemical screening in a zebrafish model of leukemia stem cell xenotransplantation. PLoS ONE
2014, 9, e85439. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1550 11 of 15
19. Yang, X.J.; Cui, W.; Gu, A.; Xu, C.; Yu, S.C.; Li, T.T.; Cui, Y.H.; Zhang, X.; Bian, X.W. A novel zebrafish
xenotransplantation model for study of glioma stem cell invasion. PLoS ONE 2013, 8, e61801. [CrossRef]
[PubMed]
20. Moshal, K.S.; Ferri-Lagneau, K.F.; Haider, J.; Pardhanani, P.; Leung, T. Discriminating different cancer cells
using a zebrafish in vivo assay. Cancers 2011, 3, 4102–4113. [CrossRef] [PubMed]
21. Von Massenhausen, A.; Sanders, C.; Bragelmann, J.; Konantz, M.; Queisser, A.; Vogel, W.; Kristiansen, G.;
Duensing, S.; Schrock, A.; Bootz, F.; et al. Targeting DDR2 in head and neck squamous cell carcinoma with
dasatinib. Int. J. Cancer 2016, 139, 2359–2369. [CrossRef] [PubMed]
22. Ochoa-Alvarez, J.A.; Krishnan, H.; Pastorino, J.G.; Nevel, E.; Kephart, D.; Lee, J.J.; Retzbach, E.P.; Shen, Y.;
Fatahzadeh, M.; Baredes, S.; et al. Antibody and lectin target podoplanin to inhibit oral squamous carcinoma
cell migration and viability by distinct mechanisms. Oncotarget 2016, 6, 9045–9060. [CrossRef] [PubMed]
23. Shin, Y.S.; Cha, H.Y.; Lee, B.S.; Kang, S.U.; Hwang, H.S.; Kwon, H.C.; Kim, C.H.; Choi, E.C. Anti-cancer
Effect of Luminacin, a Marine Microbial Extract, in Head and Neck Squamous Cell Carcinoma Progression
via Autophagic Cell Death. Cancer Res. Treat. 2016, 48, 738–752. [CrossRef] [PubMed]
24. Michailidou, C.; Jones, M.; Walker, P.; Kamarashev, J.; Kelly, A.; Hurlstone, A.F. Dissecting the roles of Raf-
and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model. Dis. Models
Mech. 2009, 2, 399–411. [CrossRef] [PubMed]
25. Martins, V.L.; Caley, M.P.; Moore, K.; Szentpetery, Z.; Marsh, S.T.; Murrell, D.F.; Kim, M.H.; Avari, M.;
McGrath, J.A.; Cerio, R.; et al. Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous
SCC. J. Natl. Cancer Inst. 2015, 108. [CrossRef]
26. Xiong, P.; Xiao, L.Y.; Yang, R.; Guo, Q.; Zhao, Y.Q.; Li, W.; Sun, Y. Flotillin-1 promotes cell growth and
metastasis in oral squamous cell carcinoma. Neoplasma 2013, 60, 395–405. [CrossRef] [PubMed]
27. Xiong, P.; Li, Y.X.; Tang, Y.T.; Chen, H.G. Proteomic analyses of Sirt1-mediated cisplatin resistance in OSCC
cell line. Protein J. 2011, 30, 499–508. [CrossRef] [PubMed]
28. Sheu, J.J.; Hua, C.H.; Wan, L.; Lin, Y.J.; Lai, M.T.; Tseng, H.C.; Jinawath, N.; Tsai, M.H.; Chang, N.W.;
Lin, C.F.; et al. Functional genomic analysis identified epidermal growth factor receptor activation as the
most common genetic event in oral squamous cell carcinoma. Cancer Res. 2009, 69, 2568–2576. [CrossRef]
[PubMed]
29. Leemans, C.R.; Braakhuis, B.J.; Brakenhoff, R.H. The molecular biology of head and neck cancer. Nat. Rev.
Cancer 2011, 11, 9–22. [CrossRef] [PubMed]
30. Mouti, M.A.; Dee, C.; Coupland, S.E.; Hurlstone, A.F. Minimal contribution of ERK1/2-MAPK signalling
towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish. Oncotarget 2016,
7, 39654–39670. [CrossRef] [PubMed]
31. Chapman, A.; Fernandez del Ama, L.; Ferguson, J.; Kamarashev, J.; Wellbrock, C.; Hurlstone, A.
Heterogeneous tumor subpopulations cooperate to drive invasion. Cell Rep. 2014, 8, 688–695. [CrossRef]
[PubMed]
32. Howe, K.; Clark, M.D.; Torroja, C.F.; Torrance, J.; Berthelot, C.; Muffato, M.; Collins, J.E.; Humphray, S.;
McLaren, K.; Matthews, L.; et al. The zebrafish reference genome sequence and its relationship to the human
genome. Nature 2013, 496, 498–503. [CrossRef] [PubMed]
33. Spitsbergen, J.M.; Kent, M.L. The state of the art of the zebrafish model for toxicology and toxicologic
pathology research-advantages and current limitations. Toxicol. Pathol. 2003, 31, 62–87. [CrossRef] [PubMed]
34. Langheinrich, U.; Vacun, G.; Wagner, T. Zebrafish embryos express an orthologue of HERG and are sensitive
toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol. Appl. Pharmacol. 2003, 193,
370–382. [CrossRef] [PubMed]
35. Goldstone, J.V.; McArthur, A.G.; Kubota, A.; Zanette, J.; Parente, T.; Jönsson, M.E.; Nelson, D.R.; Stegeman, J.J.
Identification and developmental expression of the full complement of Cytochrome P450 genes in Zebrafish.
BMC Genom. 2010, 11, 643. [CrossRef] [PubMed]
36. Jeong, J.-Y.; Kwon, H.-B.; Ahn, J.-C.; Kang, D.; Kwon, S.-H.; Park, J.A.; Kim, K.-W. Functional and
developmental analysis of the blood–brain barrier in zebrafish. Brain Res. Bull. 2008, 75, 619–628. [CrossRef]
[PubMed]
37. Li, Z.H.; Alex, D.; Siu, S.O.; Chu, I.K.; Renn, J.; Winkler, C.; Lou, S.; Tsui, S.K.-W.; Zhao, H.Y.; Yan, W.R.;
et al. Combined in vivo imaging and omics approaches reveal metabolism of icaritin and its glycosides in
zebrafish larvae. Mol. BioSyst. 2011, 7, 2128–2138. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1550 12 of 15
38. Dahm, R.; Geisler, R. Learning from Small Fry: The Zebrafish as a Genetic Model Organism for Aquaculture
Fish Species. Mar. Biotechnol. 2006, 8, 329–345. [CrossRef] [PubMed]
39. Verkman, A.S. Drug discovery in academia. Am. J. Physiol. Cell Physiol. 2004, 286, C465–C474. [CrossRef]
[PubMed]
40. Berghmans, S.; Butler, P.; Goldsmith, P.; Waldron, G.; Gardner, I.; Golder, Z.; Richards, F.M.; Kimber, G.;
Roach, A.; Alderton, W.; et al. Zebrafish based assays for the assessment of cardiac, visual and gut
function—Potential safety screens for early drug discovery. J. Pharmacol. Toxicol. Methods 2008, 58, 59–68.
[CrossRef] [PubMed]
41. Hill, A.J.; Teraoka, H.; Heideman, W.; Peterson, R.E. Zebrafish as a model vertebrate for investigating
chemical toxicity. Toxicol. Sci. 2005, 86, 6–19. [CrossRef] [PubMed]
42. Saltari, A.; Truzzi, F.; Quadri, M.; Lotti, R.; Palazzo, E.; Grisendi, G.; Tiso, N.; Marconi, A.; Pincelli, C. CD271
Down-Regulation Promotes Melanoma Progression and Invasion in Three-Dimensional Models and in
Zebrafish. J. Investig. Dermatol. 2016, 136, 2049–2058. [CrossRef] [PubMed]
43. Ali, S.; Champagne, D.L.; Spaink, H.P.; Richardson, M.K. Zebrafish embryos and larvae: A new generation
of disease models and drug screens. Birth Defects Res. Part C Embryo Today Rev. 2011, 93, 115–133. [CrossRef]
[PubMed]
44. Seok, J.; Warren, H.S.; Cuenca, A.G.; Mindrinos, M.N.; Baker, H.V.; Xu, W.; Richards, D.R.;
McDonald-Smith, G.P.; Gao, H.; Hennessy, L.; et al. Genomic responses in mouse models poorly mimic
human inflammatory diseases. Proc. Natl. Acad. Sci. USA 2013, 110, 3507–3512. [CrossRef] [PubMed]
45. Veldman, M.B.; Lin, S. Zebrafish as a developmental model organism for pediatric research. Pediatr. Res.
2008, 64, 470–476. [CrossRef] [PubMed]
46. Auer, T.O.; Duroure, K.; De Cian, A.; Concordet, J.-P.; Del Bene, F. Highly efficient CRISPR/Cas9-mediated
knock-in in zebrafish by homology-independent DNA repair. Genome Res. 2014, 24, 142–153. [CrossRef]
[PubMed]
47. Gagnon, J.A.; Valen, E.; Thyme, S.B.; Huang, P.; Ahkmetova, L.; Pauli, A.; Montague, T.G.; Zimmerman, S.;
Richter, C.; Schier, A.F. Efficient Mutagenesis by Cas9 Protein-Mediated Oligonucleotide Insertion and
Large-Scale Assessment of Single-Guide RNAs. PLoS ONE 2014, 9, e98186. [CrossRef] [PubMed]
48. Krauss, J.; Frohnhöfer, H.G.; Walderich, B.; Maischein, H.M.; Weiler, C.; Irion, U.; Nüsslein-Volhard, C.
Endothelin signalling in iridophore development and stripe pattern formation of zebrafish. Biol. Open 2014,
3, 503–509. [CrossRef] [PubMed]
49. Xiao, A.; Wang, Z.; Hu, Y.; Wu, Y.; Luo, Z.; Yang, Z.; Zu, Y.; Li, W.; Huang, P.; Tong, X.; et al. Chromosomal
deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res. 2013, 41,
e141. [CrossRef] [PubMed]
50. Jung, D.W.; Kim, J.; Che, Z.M.; Oh, E.S.; Kim, G.; Eom, S.H.; Im, S.H.; Ha, H.H.; Chang, Y.T.; Williams, D.R.
A triazine compound S06 inhibits proinvasive crosstalk between carcinoma cells and stromal fibroblasts via
binding to heat shock protein 90. Chem. Biol. 2011, 18, 1581–1590. [CrossRef] [PubMed]
51. Cichon, M.A.; Szentpetery, Z.; Caley, M.P.; Papadakis, E.S.; Mackenzie, I.C.; Brennan, C.H.; O’Toole, E.A.
The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell
carcinoma. Oncogene 2014, 33, 4185–4192. [CrossRef] [PubMed]
52. Slaughter, D.P.; Southwick, H.W.; Smejkal, W. “Field cancerization” in oral stratified squamous epithelium.
Clinical implications of multicentric origin. Cancer 1953, 6, 963–968. [CrossRef]
53. Van der Weyden, L.; Patton, E.E.; Wood, G.A.; Foote, A.K.; Brenn, T.; Arends, M.J.; Adams, D.J. Cross-species
models of human melanoma. J. Pathol. 2016, 238, 152–165. [CrossRef] [PubMed]
54. Tang, Q.; Moore, J.C.; Ignatius, M.S.; Tenente, I.M.; Hayes, M.N.; Garcia, E.G.; Torres Yordan, N.; Bourque, C.;
He, S.; Blackburn, J.S.; et al. Imaging tumour cell heterogeneity following cell transplantation into optically
clear immune-deficient zebrafish. Nat. Commun. 2016, 7, 10358. [CrossRef] [PubMed]
55. White, R.M.; Sessa, A.; Burke, C.; Bowman, T.; LeBlanc, J.; Ceol, C.; Bourque, C.; Dovey, M.; Goessling, W.;
Burns, C.E.; et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell
2008, 2, 183–189. [CrossRef] [PubMed]
56. Wienholds, E.; Schulte-Merker, S.; Walderich, B.; Plasterk, R.H. Target-selected inactivation of the zebrafish
Rag1 gene. Science 2002, 297, 99–102. [CrossRef] [PubMed]
57. Patton, E.E.; Zon, L.I. The art and design of genetic screens: Zebrafish. Nat. Rev. Genet. 2001, 2, 956–966.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1550 13 of 15
58. Li, M.; Zhao, L.; Page-McCaw, P.S.; Chen, W. Zebrafish Genome Engineering Using the CRISPR-Cas9 System.
Trends Genet. 2016, 32, 815–827. [CrossRef] [PubMed]
59. Perles, Z.; Moon, S.; Ta-Shma, A.; Yaacov, B.; Francescatto, L.; Edvardson, S.; Rein, A.J.; Elpeleg, O.;
Katsanis, N. A human laterality disorder caused by a homozygous deleterious mutation in MMP21. J. Med.
Genet. 2015, 52, 840–847. [CrossRef] [PubMed]
60. Gibney, G.T.; Zager, J.S. Clinical development of dabrafenib in BRAF mutant melanoma and other
malignancies. Expert Opin. Drug Metab. Toxicol. 2013, 9, 893–899. [CrossRef] [PubMed]
61. Hwang, W.Y.; Fu, Y.; Reyon, D.; Maeder, M.L.; Tsai, S.Q.; Sander, J.D.; Peterson, R.T.; Yeh, J.R.J.; Joung, J.K.
Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 2013, 31, 227–229.
[CrossRef] [PubMed]
62. Ablain, J.; Durand, E.M.; Yang, S.; Zhou, Y.; Zon, L.I. A CRISPR/Cas9 Vector System for Tissue-Specific Gene
Disruption in Zebrafish. Dev. Cell 2015, 32, 756–764. [CrossRef] [PubMed]
63. Ekedahl, H.; Cirenajwis, H.; Harbst, K.; Carneiro, A.; Nielsen, K.; Olsson, H.; Lundgren, L.; Ingvar, C.;
Jonsson, G. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma
cohort. Br. J. Dermatol. 2013, 169, 1049–1055. [CrossRef] [PubMed]
64. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.;
Bottomley, W.; et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949–954. [CrossRef]
[PubMed]
65. Patton, E.E.; Widlund, H.R.; Kutok, J.L.; Kopani, K.R.; Amatruda, J.F.; Murphey, R.D.; Berghmans, S.;
Mayhall, E.A.; Traver, D.; Fletcher, C.D.; et al. BRAF mutations are sufficient to promote nevi formation and
cooperate with p53 in the genesis of melanoma. Curr. Biol. 2005, 15, 249–254. [CrossRef] [PubMed]
66. Ceol, C.J.; Houvras, Y.; Jane-Valbuena, J.; Bilodeau, S.; Orlando, D.A.; Battisti, V.; Fritsch, L.; Lin, W.M.;
Hollmann, T.J.; Ferre, F.; et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma
and accelerates its onset. Nature 2011, 471, 513–517. [CrossRef] [PubMed]
67. Flaherty, K.T.; Hodi, F.S.; Fisher, D.E. From genes to drugs: Targeted strategies for melanoma. Nat. Rev.
Cancer 2012, 12, 349–361. [CrossRef] [PubMed]
68. Kim, M.K.; Bang, C.Y.; Kim, M.Y.; Lee, J.H.; Ro, H.; Choi, M.S.; Kim, D.I.; Jang, Y.P.; Choung, S.Y.
Traditional herbal prescription LASAP-C inhibits melanin synthesis in B16F10 melanoma cells and zebrafish.
BMC Complement. Altern. Med. 2016, 16, 223. [CrossRef] [PubMed]
69. Yen, J.; White, R.M.; Wedge, D.C.; Van Loo, P.; de Ridder, J.; Capper, A.; Richardson, J.; Jones, D.; Raine, K.;
Watson, I.R.; et al. The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish
models. Genome Biol. 2013, 14, 1–14. [CrossRef] [PubMed]
70. Santoriello, C.; Gennaro, E.; Anelli, V.; Distel, M.; Kelly, A.; Köster, R.W.; Hurlstone, A.; Mione, M. Kita
Driven Expression of Oncogenic HRAS Leads to Early Onset and Highly Penetrant Melanoma in Zebrafish.
PLoS ONE 2010, 5, e15170. [CrossRef] [PubMed]
71. Lister, J.A.; Capper, A.; Zeng, Z.; Mathers, M.E.; Richardson, J.; Paranthaman, K.; Jackson, I.J.; Patton, E.E.
A Conditional Zebrafish MITF Mutation Reveals MITF Levels Are Critical for Melanoma Promotion vs.
Regression In Vivo. J. Investig. Dermatol. 2014, 134, 133–140. [CrossRef] [PubMed]
72. Taylor, K.L.; Lister, J.A.; Zeng, Z.; Ishizaki, H.; Anderson, C.; Kelsh, R.N.; Jackson, I.J.; Patton, E.E.
Differentiated melanocyte cell division occurs in vivo and is promoted by mutations in Mitf. Development
2011, 138, 3579–3589. [CrossRef] [PubMed]
73. Zeng, Z.; Johnson, S.L.; Lister, J.A.; Patton, E.E. Temperature-sensitive splicing of mitfa by an intron mutation
in zebrafish. Pigment Cell Melanoma Res. 2015, 28, 229–232. [CrossRef] [PubMed]
74. Garraway, L.A.; Widlund, H.R.; Rubin, M.A.; Getz, G.; Berger, A.J.; Ramaswamy, S.; Beroukhim, R.;
Milner, D.A.; Granter, S.R.; Du, J.; et al. Integrative genomic analyses identify MITF as a lineage survival
oncogene amplified in malignant melanoma. Nature 2005, 436, 117–122. [CrossRef] [PubMed]
75. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy. Nature 2007, 445,
851–857. [CrossRef] [PubMed]
76. Levy, C.; Khaled, M.; Fisher, D.E. MITF: Master regulator of melanocyte development and melanoma
oncogene. Trends Mol. Med. 2006, 12, 406–414. [CrossRef] [PubMed]
77. Opdecamp, K.; Nakayama, A.; Nguyen, M.T.; Hodgkinson, C.A.; Pavan, W.J.; Arnheiter, H. Melanocyte
development in vivo and in neural crest cell cultures: Crucial dependence on the Mitf basic-helix-
loop-helix-zipper transcription factor. Development 1997, 124, 2377–2386. [PubMed]
Int. J. Mol. Sci. 2017, 18, 1550 14 of 15
78. Haq, R.; Fisher, D. Biology and clinical relevance of the micropthalmia family of transcription factors in
human cancer. J. Clin. Oncol. 2011, 29, 3474–3482. [CrossRef] [PubMed]
79. Koludrovic, D.; Davidson, I. MITF, the Janus transcription factor of melanoma. Future Oncol. 2013, 9, 235–244.
[CrossRef] [PubMed]
80. Yajima, I.; Kumasaka, M.Y.; Thang, N.D.; Goto, Y.; Takeda, K.; Iida, M.; Ohgami, N.; Tamura, H.;
Yamanoshita, O.; Kawamoto, Y.; et al. Molecular Network Associated with Mitf in Skin Melanoma
Development and Progression. J. Skin Cancer 2011, 2011, 730170. [CrossRef] [PubMed]
81. McGill, G.G.; Horstmann, M.; Widlund, H.R.; Du, J.; Motyckova, G.; Nishimura, E.K.; Lin, Y.-L.;
Ramaswamy, S.; Avery, W.; Ding, H.-F.; et al. Bcl2 Regulation by the Melanocyte Master Regulator Mitf
Modulates Lineage Survival and Melanoma Cell Viability. Cell 2002, 109, 707–718. [CrossRef]
82. Oberoi-Khanuja, T.K.; Karreman, C.; Larisch, S.; Rapp, U.R.; Rajalingam, K. Role of Melanoma Inhibitor
of Apoptosis (ML-IAP) Protein, a Member of the Baculoviral IAP Repeat (BIR) Domain Family, in the
Regulation of C-RAF Kinase and Cell Migration. J. Biol. Chem. 2012, 287, 28445–28455. [CrossRef] [PubMed]
83. Vucic, D.; Stennicke, H.R.; Pisabarro, M.T.; Salvesen, G.S.; Dixit, V.M. ML-IAP, a novel inhibitor of apoptosis
that is preferentially expressed in human melanomas. Curr. Biol. 2000, 10, 1359–1366. [CrossRef]
84. Widmer, D.S.; Hoek, K.S.; Cheng, P.F.; Eichhoff, O.M.; Biedermann, T.; Raaijmakers, M.I.; Hemmi, S.;
Dummer, R.; Levesque, M.P. Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent
phenotype switching. J. Investig. Dermatol. 2013, 133, 2436–2443. [CrossRef] [PubMed]
85. McGill, G.G.; Haq, R.; Nishimura, E.K.; Fisher, D.E. c-Met Expression Is Regulated by Mitf in the Melanocyte
Lineage. J. Biol. Chem. 2006, 281, 10365–10373. [CrossRef] [PubMed]
86. Hartman, M.L.; Czyz, M. Pro-Survival Role of MITF in Melanoma. J. Investig. Dermatol. 2015, 135, 352–358.
[CrossRef] [PubMed]
87. Carreira, S.; Goodall, J.; Aksan, I.; La Rocca, S.A.; Galibert, M.-D.; Denat, L.; Larue, L.; Goding, C.R.
Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005,
433, 764–769. [CrossRef] [PubMed]
88. Cheng, C.; Yang, H.W.; Shang, J.F.; Li, W.W.; Sun, Q.Z.; Chen, X.; Cao, Z.X.; Yao, S.H.; Yang, S.Y. Identification
of a small molecule that downregulates MITF expression and mediates antimelanoma activity in vitro.
Melanoma Res. 2016, 26, 117–124. [CrossRef] [PubMed]
89. Lévesque, M.; Feng, Y.; Jones, R.A.; Martin, P. Inflammation drives wound hyperpigmentation in zebrafish by
recruiting pigment cells to sites of tissue damage. Dis. Models Mech. 2013, 6, 508–515. [CrossRef] [PubMed]
90. Chen, L.; Ren, X.; Liang, F.; Li, S.; Zhong, H.; Lin, S. Characterization of two novel small molecules
targeting melanocyte development in zebrafish embryogenesis. Pigment Cell Melanoma Res. 2012, 25, 446–453.
[CrossRef] [PubMed]
91. Wu, S.-Y.; Wang, H.-M.; Wen, Y.-S.; Liu, W.; Li, P.-H.; Chiu, C.-C.; Chen, P.-C.; Huang, C.-Y.; Sheu, J.-H.;
Wen, Z.-H. 4-(Phenylsulfanyl)butan-2-One Suppresses Melanin Synthesis and Melanosome Maturation In
Vitro and In Vivo. Int. J. Mol. Sci. 2015, 16, 20240–20257. [CrossRef] [PubMed]
92. White, R.M.; Cech, J.; Ratanasirintrawoot, S.; Lin, C.Y.; Rahl, P.B.; Burke, C.J.; Langdon, E.; Tomlinson, M.L.;
Mosher, J.; Kaufman, C.; et al. DHODH modulates transcriptional elongation in the neural crest and
melanoma. Nature 2011, 471, 518–522. [CrossRef] [PubMed]
93. Guo, J.; Price, D.H. RNA Polymerase II Transcription Elongation Control. Chem. Rev. 2013, 113, 8583–8603.
[CrossRef] [PubMed]
94. Tan, J.L.; Fogley, R.D.; Flynn, R.A.; Ablain, J.; Yang, S.; Saint-Andre, V.; Fan, Z.P.; Do, B.T.; Laga, A.C.;
Fujinaga, K.; et al. Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to
Suppress Melanoma. Mol. Cell 2013, 62, 34–46. [CrossRef] [PubMed]
95. Ablain, J.; Poirot, B.; Esnault, C.; Lehmann-Che, J. p53 as an Effector or Inhibitor of Therapy Response.
Cold Spring Harb. Perspect. Med. 2016, 6, a026260. [CrossRef] [PubMed]
96. Le, X.; Pugach, E.K.; Hettmer, S.; Storer, N.Y.; Liu, J.; Wills, A.A.; DiBiase, A.; Chen, E.Y.; Ignatius, M.S.;
Poss, K.D.; et al. A novel chemical screening strategy in zebrafish identifies common pathways in
embryogenesis and rhabdomyosarcoma development. Development 2013, 140, 2354–2364. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2017, 18, 1550 15 of 15
97. Thomas, H.E.; Mercer, C.A.; Carnevalli, L.S.; Park, J.; Andersen, J.B.; Conner, E.A.; Tanaka, K.; Matsutani, T.;
Iwanami, A.; Aronow, B.J.; et al. mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression,
and Autophagy in Hepatocellular Carcinoma. Sci. Transl. Med. 2012, 4, 139ra84. [CrossRef] [PubMed]
98. Lasithiotakis, K.G.; Sinnberg, T.W.; Schittek, B.; Flaherty, K.T.; Kulms, D.; Maczey, E.; Garbe, C.; Meier, F.E.
Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates
Invasive Growth of Melanoma Cells. J. Investig. Dermatol. 2008, 128, 2013–2023. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
